IC
IBRX icon

IEQ Capital’s ImmunityBio IBRX Stock Holding History

IEQ Capital’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$132K Sell
15,100
-10,000
-40% -$75.7K ﹤0.01% 1901
2026
Q1 		$193K Buy
25,100
+15,100
+151% +$103K ﹤0.01% 1708
2025
Q4 		$19.8K Sell
10,000
-11,476
-53% -$26K ﹤0.01% 1827
2025
Q3 		$52.8K Sell
21,476
-8,305
-28% -$21.4K ﹤0.01% 1796
2025
Q2 		$78.6K Buy
+29,781
New +$80.1K ﹤0.01% 1740

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IEQ Capital's IBRX Position: Q2 2026 in Review

IEQ Capital reduced its ImmunityBio (IBRX) stake by 40% in Q2 2026, selling an estimated $75.7K and leaving 15,100 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #1901.

IEQ Capital first reported a position in IBRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $193K in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • IEQ Capital held 15,100 shares of ImmunityBio worth $132K as of Q2 2026.
  • IEQ Capital sold 10,000 ImmunityBio shares in Q2 2026, an estimated $75.7K.
  • ImmunityBio made up ﹤0.01% of IEQ Capital's portfolio in Q2 2026, its #1901 holding.
  • IEQ Capital first reported a position in ImmunityBio in Q2 2025 and has held it in 5 quarters since.
  • IEQ Capital's ImmunityBio position peaked at $193K in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on IEQ Capital's 13F filing for Q2 2026, filed 11 Aug 2026.